Insider Trading July 13, 2026 11:39 AM

TOI Insider Activity: Jorey Chernett Acquires $87,750 in Oncology Institute Shares Amid Refinancing and Analyst Upgrades

10% shareholder increases stake as the company navigates debt restructuring and expands growth outlook.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
TOI

Jorey Chernett, a significant 10% shareholder in The Oncology Institute, Inc. (NASDAQ: TOI), executed a direct purchase of 15,000 shares on July 10, 2026, valued at $87,750. This transaction brings Chernett's total holding to 10,630,858 shares. The insider buying activity occurs as TOI trades near its 52-week high of $6.11, supported by recent corporate developments including a successful $86 million debt refinancing with OrbiMed and multiple analyst upgrades from BTIG, Lake Street, and Needham.

TOI Insider Activity: Jorey Chernett Acquires $87,750 in Oncology Institute Shares Amid Refinancing and Analyst Upgrades
TOI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • 10% shareholder Jorey Chernett acquired 15,000 shares at a weighted average price of $5.85, increasing his total stake to 10,630,858 shares.
  • The Oncology Institute successfully refinanced $86 million in debt with OrbiMed, utilizing a new $75 million term loan maturing in 2031 and approximately $11 million in cash to repay a senior secured convertible note with Deerfield Partners.
  • Analyst sentiment turned more positive, with BTIG raising its price target to $9, Lake Street initiating coverage with a $10 target, and Needham increasing its target to $7 following discussions with company executives.

Jorey Chernett, a 10% owner of Oncology Institute, Inc. (NASDAQ:TOI), executed a direct purchase of the company's common stock on July 10, 2026. The transaction involved the acquisition of 15,000 shares for a total value of $87,750. The shares were bought at prices ranging from $5.82 to $5.90 per share. The reported weighted average price for these transactions was $5.85 per share. The insider purchase comes as TOI trades near its 52-week high of $6.11, with the stock delivering an impressive 88% return over the past year. Following this direct purchase, Mr. Chernett now holds a total of 10,630,858 shares of Oncology Institute common stock. The company, valued at $598 million, has shown strong revenue growth of 35% over the last twelve months, though it remains unprofitable with an EPS of -$0.37.

Key Points:

  • 10% shareholder Jorey Chernett acquired 15,000 shares at a weighted average price of $5.85, increasing his total stake to 10,630,858 shares.
  • The Oncology Institute successfully refinanced $86 million in debt with OrbiMed, utilizing a new $75 million term loan maturing in 2031 and approximately $11 million in cash to repay a senior secured convertible note with Deerfield Partners.
  • Analyst sentiment turned more positive, with BTIG raising its price target to $9, Lake Street initiating coverage with a $10 target, and Needham increasing its target to $7 following discussions with company executives.

Risks and Uncertainties:

  • The company remains unprofitable with an EPS of -$0.37, highlighting ongoing financial challenges despite revenue growth.
  • The refinancing transaction did not involve raising additional equity, potentially limiting immediate capital expansion options.
  • Market volatility near the 52-week high of $6.11 could impact future trading performance despite recent positive developments.

These recent developments highlight the company's strategic moves and potential growth opportunities in the healthcare sector. The Oncology Institute's Chief Medical Officer, Yale D. Podnos, is set to speak at the APG Spring Conference in San Diego, discussing the role of specialists in value-based healthcare delivery. This engagement underscores the company's focus on expanding its influence within the specialty finance and healthcare delivery sectors.

InvestingPro offers 7 additional exclusive tips for TOI, plus comprehensive Pro Research Reports covering 1,400+ US stocks with expert analysis and actionable insights. ProPicks AI evaluates TOI every month against thousands of alternatives using 100+ financial metrics. It found Siemens Energy (+231.5%) and Sandisk (+189%) before the crowd did. Could TOI be next—or is there a better opportunity in the same space?

Risks

  • The company remains unprofitable with an EPS of -$0.37, highlighting ongoing financial challenges despite revenue growth.
  • The refinancing transaction did not involve raising additional equity, potentially limiting immediate capital expansion options.
  • Market volatility near the 52-week high of $6.11 could impact future trading performance despite recent positive developments.

More from Insider Trading

BillionToOne Chief Executive Oguzhan Atay Offloads $1.57 Million in Equity Jul 13, 2026 Consortium of Entities Acquires $1.23M in Energizer Holdings Shares Amid Valuation Gap Jul 13, 2026 BillionToOne CPO Shan Riku Sakakibara Executes Pre-Arranged Stock Sale Jul 13, 2026 Datadog Director Amit Agarwal Disposes of $5.35 Million in Class A Shares Jul 13, 2026 Workday Co-Founder David Duffield Executes $14.7 Million Share Sale Under Pre-Arranged Plan Jul 13, 2026